



Aston University  
Birmingham


Good drugs for bad bugs:

*Finding new antibiotics  
for tuberculosis*



Dr Jonathan Cox  
J.A.G.Cox@aston.ac.uk  
@DrJonathanCox

# TB Drug Discovery Pipeline



- Diarylquinolines
- InhA inhibitors
- LeuRS inhibitors
- Mycobacterial gyrase inhibitors
- Pyrazinamide analogues
- Riminophenazines
- Ruthenium (II) complexes
- Spectinamides
- Translocase 1 inhibitors

- CPZEN-45
- DC-159a
- Q201
- SPR-10199
- SQ609
- SQ641

- BTZ043
- TBA-354

- AZD5847
- Bedaquiline (TMC207)
- Linezolid
- Novel regimens
- PA-824
- Rifapentine
- SQ109
- Sutezolid (PNU-100480)


- Delamanid (OPC67683)
- Gatifloxacin
- Moxifloxacin
- Rifapentine

## Chemical classes

- Fluoroquinolone
- Rifamycin
- Oxazolidinone
- Nitroimidazole
- Diarylquinoline
- Benzothiazinone

Nature Reviews Drug Discovery 12, 388–404 (2013)

# Strategies in AB drug discovery



# Drug to target

1) Whole cell phenotypic HTS

2) Generate spontaneous mutants



3) Validate resistance phenotype

4) WGS

5) Bioinformatics and SNP identification

7) MOA studies

6) Genetic validation



Pan-assay interference compounds (PAINS)  
Baell and Walters *Nature* 2014 (513)

# Chasing your tail... or the wrong target

OPEN ACCESS Freely available online

PLOS ONE

## Tetrahydropyrazolo[1,5-*a*]Pyrimidine-3-Carboxamide and *N*-Benzyl-6',7'-Dihydrospiro[Piperidine-4,4'-Thieno[3,2-*c*]Pyran] Analogues with Bactericidal Efficacy against *Mycobacterium tuberculosis* Targeting MmpL3

Modesto J. Remuiñán<sup>1\*</sup>, Esther Pérez-Herrán<sup>1</sup>, Joaquín Rullás<sup>1</sup>, Carlos Alemparte<sup>1</sup>, María Martínez-Hoyos<sup>1</sup>, David J. Dow<sup>2</sup>, Johnson Afari<sup>2</sup>, Nalini Mehta<sup>2</sup>, Jorge Esquivias<sup>1</sup>, Elena Jiménez<sup>1</sup>, Fátima Ortega-Muro<sup>1</sup>, María Teresa Fraile-Gabaldón<sup>1</sup>, Vickey L. Spivey<sup>2</sup>, Nicholas J. Loman<sup>3</sup>, Mark J. Pallen<sup>3</sup>, Chrystala Constantinidou<sup>3</sup>, Douglas J. Minick<sup>4</sup>, Mónica Cacho<sup>1</sup>, María José Rebollo-López<sup>1</sup>, Carolina González<sup>1</sup>, Verónica Sousa<sup>1</sup>, Iñigo Angulo-Barturen<sup>1</sup>, Alfonso Mendoza-Losana<sup>1</sup>, David Barros<sup>1</sup>, Gurdyal S. Besra<sup>3</sup>, Lluís Ballell<sup>1</sup>, Nicholas Cammack<sup>1</sup>

<sup>1</sup> Diseases of the Developing World, GlaxoSmithKline, Tres Cantos, Madrid, Spain, <sup>2</sup> Molecular and Cellular Technologies, GlaxoSmithKline, Stevenage, United Kingdom, <sup>3</sup> School of Biosciences, University of Birmingham, Edgbaston, United Kingdom, <sup>4</sup> Department of Analytical Chemistry, GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America



### CHALLENGES:

- WGS has limitations
- It sometimes gives us a hint
- Its not the only strategy
- HTS only as good as the library

nature  
microbiology


Article | Published: 18 January 2016

## THPP target assignment reveals EchA6 as an essential fatty acid shuttle in mycobacteria


Jonathan A. G. Cox, Katherine A. Abrahams, Carlos Alemparte, Sonja Ghidelli-Disse, Joaquín Rullas, Iñigo Angulo-Barturen, Albel Singh, Sudagar S. Gurcha, Vijayashankar Nataraj, Stephen Bethell, Modesto J. Remuiñán, Lourdes Encinas, Peter J. Jarvis, Nicholas C. Cammack, Apoorva Bhatt, Ulrich Kruse, Marcus Bantscheff, Klaus Fütterer , David Barros, Lluís Ballell , Gerard Drewes & Gurdyal S. Besra 

Nature Microbiology 1, Article number: 15006 (2016) | [Download Citation](#) ↓

# Strategies in AB drug discovery



# Target to drug




## Mycobacterial Dihydrofolate Reductase Inhibitors Identified Using Chemogenomic Methods and *In Vitro* Validation

Grace Mugumbate<sup>1</sup>, Katherine A. Abrahams<sup>2</sup>, Jonathan A. G. Cox<sup>2</sup>, George Papadatos<sup>1</sup>, Gerard van Westeren<sup>1</sup>, Joël Lelievre<sup>2</sup>, Szymon T. Calus<sup>2</sup>, Nicholas J. Loman<sup>1</sup>, Lluis Belliell<sup>3</sup>, David Barros<sup>3</sup>, John P. Overington<sup>1\*</sup>, Gurdayal S. Beera<sup>2\*</sup>

**1** European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdom, **2** Institute of Microbiology and Infection (IMI), School of Biociences, University of Birmingham, Edgbaston, Birmingham, United Kingdom, **3** Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain


\* [jo.p@ebi.ac.uk](mailto:jo.p@ebi.ac.uk) (JPO); [g.beera@bham.ac.uk](mailto:g.beera@bham.ac.uk) (GSB)



### CHALLENGES:

- Do the drugs get in?
- Are they active?
- Do they engage target?
- You won't discover a new drug target

# In an ideal world.....



# A combined approach...

- Overexpress important genes
- Screen against 10,000 known TB inhibitors
- Look for  $IC_{50}$  shift with overexpressing strain



- New targets
- Good inhibitors
- Whole cell activity
- Target engagement

